Protocol Ledger

NCT05011058 · Phase II · TERMINATED

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

Interventional Phase II clinical trial protocol NCT05011058 sponsored by Viracta Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-28 Enrollment: 102 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05011058
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)102 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05011058
Protocol FieldVerified Registry Value
NCT IdentifierNCT05011058
Consolidated Lead SponsorViracta Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment102 participants (ACTUAL)
Registered Start Date2021-05-28
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI